All the latest news on the marijuana space delivered directly to your inbox.
Read our Investor Dashboard on OTC:ABCCF TSX.v ABCN
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

13x13x1 READ MORE
Read the Investors Guide To Newly Emerging Marijuana Markets 
Harvest One Announces $15 Million Bought Short form Prospectus Offering of Convertible Debenture Units

Harvest One Cannabis Inc. (TSX VENTURE:HVST) announces that is has entered into an agreement with Mackie Research Capital Corporation (as the lead underwriter and sole bookrunner), on behalf of a syndicate of Underwriters pursuant to which the Underwriters have agreed to purchase, on a bought deal basis and sell to the public, 15,000 convertible debenture units of the Company at a price of $1,000 per Debenture Unit for aggregate gross proceeds of $15,000,000.

13x13x1 READ MORE
iAnthus Announces Closing of $12 Million Offering and $3.7 Million Non-Brokered Private Placement

iAnthus Capital Holdings, Inc., (CSE: IAN) (CSE: IAN.CN) (CNSX: IAN), announces that it closed its previously announced offering of 7,072,500 common shares of the Company at a price of $1.70 per Common Share for aggregate gross proceeds to the Company of $12,023,250..

13x13x1 READ MORE
Tokyo Smoke Beltline in Calgary opens December 7

First Tokyo Smoke to open outside of Ontario for the premium cannabis lifestyle brand.

13x13x1 READ MORE
BBC Capital - Meet Canada’s ‘weed sommelier’

Rade Kovacevic is a cannabis connoisseur. As the head of customer experience at Canopy Growth Corporation, a cannabis producer in Ontario, Canada, his job is to make sure his firm provides the highest quality marijuana. His company produces medicinal cannabis for patients across Canada, where recreational use is illegal but doctors can prescribe it to patients for medical purposes, such as pain management.

13x13x1 READ MORE
Please see full disclaimers on the website applicable to all content provided by TSI, wherever published or re-published:

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
32x32x1   32x32x2
9375 E Shea Blvd Ste 100
Scottsdale 85260
©2019, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.